期刊文献+

急性ST段抬高型心肌梗死患者经皮冠状动脉介入治疗前后T波峰末间期的变化过程及其与恶性室性心律失常的关系

下载PDF
导出
摘要 目的探究急性ST段抬高型心肌梗死(STEMI)患者经皮冠状动脉介入治疗(PCI)前后T波峰末间期(Tpec)的变化过程及其与恶性室性心律失常(MVA)的关系。方法178例STEMI患者作为研究对象,均进行PCI,根据患者PCI后是否发生MVA分为MVA组(42例)和非MVA组(136例)。分析PCI后发生MVA的危险因素。结果178例患者中,Tpec≥100 ms的患者92例,Tpec<100 ms的患者86例。发生MVA的患者42例(MVA组),发生MVA的患者136例(非MVA组)。行PCI后,Tpec≥100 ms的患者MVA发生率为35.9%(33/92),高于Tpec<100 ms患者的10.5%(9/86),差异具有统计学意义(χ^(2)=15.912,P<0.05)。发生MVA的患者PCI后Tpec降低缓慢,具有波动趋势;未发生MVA的患者PCI后6 h表现出持续下降趋势。Logistic单因素回归分析显示:吸烟、心率、术后Tpec≥100 ms、PCI后TIMI血流<2级、Killip心功能分级>1级、未应用β受体阻滞剂是PCI后发生MVA的危险因素(P<0.05)。Logistic多因素回归分析显示:术后Tpec≥100 ms、PCI后TIMI血流<2级、Killip心功能分级>1级、未应用β受体阻滞剂是PCI后发生MVA的独立危险因素(P<0.05)。结论在治疗过程中,及时改善梗死相关冠状动脉血流具有重要意义,有助于改善存活心肌的电生理功能,进一步防控MVA。采用PCI能够对STEMI患者的病情进行控制,其PCI后Tpec降低缓慢是导致MVA的危险因素,对于控制病情发展,做好不良预后预防具有重要作用。
作者 葛现伟
出处 《中国实用医药》 2022年第9期66-68,共3页 China Practical Medicine
  • 相关文献

参考文献12

二级参考文献102

  • 1熊跃.阿托伐他汀联合替罗非班治疗急性心肌梗死的效果观察.实用心脑肺血管病杂志,2014,4(1):121-122.
  • 2LLOYD - JONES 0, ADAMS RJ, BROWN TM, et 01. Executive summary: heart disease and stroke statistics- 2010 update. A report from the American Heart Associaton[J]. Circulation, 2010, 121 (7): 948-954.
  • 3STIERMAIER T, DESCH S, SCHULER G, et 01. Reperfusion strategies in ST - segment elevation myocardial infarction[J] . Minerva Med, 2013, 104 ( 4): 391-411.
  • 4TOPOL EJ, CALIFF RM, DEORGE OJ, et 01. A randomizedtrial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardialinfarction[J]. N Engl J Med, 1987, 317 (10): 581-588.
  • 5SIMOONS ML, ARNOLD AE, BIETRIU A, et 01. Thrombolysiswith tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronaryangioplasty[J]. Lancet, 1988, 331(8579): 197-203.
  • 6The TIMI Research Group. Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. The TIMI II A results[J]. JAMA, 1988, 260(18): 2849-2858.
  • 7ROGERSWJ, BAlM OS, GORE JM, et 01. Comparison ofimmediate invasive, delayed invasive, and conservative strategies after tissue - type plasminogen activator. Results of the Thrombolysis in Myocardial Infarction (TIMl) Phase II-A trialjJ]. Circulation, 1990, 81 (5): 1457-1476.
  • 8The SWIFT Trial Research Group. SWIFT trial of delayedelective intervention v conservative treatment after thrombolysis with anistreplase in acute myocardial infarction[J]. BMJ, 1991,302(6776): 555-560.
  • 9WALLER BP, ROTHBAUM DA, PINKERTON CA, et al. Statusof the myocardium and infarct related coronary artery in 10 necropsy patients with acute recanalization using pharmacologic (streptokinase, r - tissue plasminogen activator), mechanical (percut-aneous transluminal coronary angioplasty ) , or combined types of reperfusion therapy[J]. J Am Coil Cardiol , 1987, 9 (4) : 785-801.
  • 10KASTRATI A, MEHILLl J, SCHLOTTERBERK K, et 01. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: A randomized controlledtrial[J]. JAMA, 2004, 291(8): 947-954.

共引文献307

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部